David Graham, MD, FDA’s Associate Director of Science and Medicine who, throughout his career, has been a thorn for FDA managers by identifying hazardous drug effects. In 1999, his data helped identify the risk of liver damage from Pfizer’s diabetes drug Rezulin . . . Continue reading →
Part III. The Untouchable Third Rail in Healthcare—The Vaccine Controversy: Core Issues Continue reading →
The decision to suspend the trial is viewed as highly questionable, raising disturbing questions about the role that marketing played–especially in light of the fact that Zytiga’s patent is due to expire in 2017.
On Friday, April 6, the FDA approved another of Eli Lilly’s "breakthroughs" whose clinical value is questionable (at best). Continue reading →
The single National Biodefense Science Board panelist who voted against the recommendation in support of an anthrax vaccine test in children was Patricia Quinlisk, M.D., M.P.H. State Epidemiologist and Medical Director Iowa Department of Public Health, who chaired the NBSB panel. Continue reading →
Dr. Charles Schulz is scheduled to present "How to help parents of a first psychotic episode patient," at Annual APA Meeting –it is closed to public. What is it that psychiatrists and the APA do not want parents or the public to know?
Continue reading →
Forbes Magazine reports "How one company turned a rejection into a thumbs up, and what it could mean for the drug industry as a whole." Continue reading →
A document filed in Federal District Court, Orlando Fla, by plaintiffs "in response to AstraZeneca’s motion to exclude evidence and argument about Dr. Macfadden’s personal relationships," sheds light on yet another facet of manipulation–sexual exploitation.
Continue reading →
State Attorney Generals are investigating the off-label marketing of Zyprexa–which, if documented is a federal crime. Continue reading →